GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Astec Lifesciences Ltd

Astec Lifesciences Q2 FY27 Consolidated Loss After Tax Rs. 3,739.71 lakh

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 26 Oct 2026, 05:12 PM IST  ·  BSE ID: f5814c76-d4b9-49c9-9e78-7714eb7c2675
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a consolidated loss of Rs. 3,739.71 lakh for the September 2026 quarter, with revenue at Rs. 7,202.01 lakh.
🤖 AI Summary
  • Astec Lifesciences approved Unaudited Financial Results (Standalone & Consolidated) for Q2 and Half Year ended September 30, 2026.
  • Consolidated Loss for the Period stood at Rs. 3,739.71 lakh for the quarter ended September 30, 2026.
  • Consolidated Revenue From Operations was Rs. 7,202.01 lakh for the quarter ended September 30, 2026.
  • Consolidated Basic Earnings Per Share (non-annualized) was Rs. (16.79) for the quarter.
  • The Statutory Auditors issued unmodified Limited Review Reports on both Standalone and Consolidated results.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue From Operations (Q2 FY27)
Rs. 7,202.01 lakh
Not comparable — limited prior period data.
Consolidated Loss For The Period (Q2 FY27)
(Rs. 3,739.71) lakh
Not comparable — limited prior period data.
Consolidated Loss Before Tax (H1 FY27)
(Rs. 5,616.60) lakh
Not comparable — limited prior period data.
Consolidated Total Assets (As of Sep 30, 2026)
Rs. 79,441.82 lakh
Not comparable — limited prior period data.
Consolidated Basic EPS (Q2 FY27)
(Rs. 16.79)
Not comparable — limited prior period data.
🏢 How This Affects the Company
💰
Financial Impact
The company's consolidated financials show a loss after tax of Rs. 3,739.71 lakh for the quarter ended September 30, 2026, contributing to a half-year consolidated loss of Rs. 5,610.44 lakh. Total consolidated assets decreased from Rs. 94,203.82 lakh as of March 31, 2026, to Rs. 79,441.82 lakh as of September 30, 2026.
⚠️
Risk Impact
The ongoing consolidated losses, totaling Rs. 5,610.44 lakh for the half-year ended September 30, 2026, represent a continued financial risk to the company.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the reported consolidated loss after tax of Rs. 3,739.71 lakh for the quarter and Rs. 5,610.44 lakh for the half-year ended September 30, 2026.
🔍
Management Signal
The approval of these unaudited financial results and noting of unmodified limited review reports indicates management's adherence to regulatory disclosure requirements.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 results — monitor revenue and loss trends.
Management commentary on future outlook.
Updates on strategies to improve profitability.
HIGH RISK The company reported significant consolidated losses for the quarter and half-year, combined with a decline in total assets.
💡 Investor Takeaway
Astec Lifesciences reported a consolidated loss after tax of Rs. 3,739.71 lakh for Q2 FY27, compared to a loss of Rs. 2,441.70 lakh in Q2 FY26. Consolidated revenue from operations for Q2 FY27 was Rs. 7,202.01 lakh, a decrease from Rs. 7,372.06 lakh in Q2 FY26. Half-year consolidated loss was Rs. 5,610.44 lakh.
⚖️ Strengths & Concerns

⚠️ Concerns

  • Consolidated Loss for the Period increased to Rs. 3,739.71 lakh for Q2 FY27, compared to Rs. 2,441.70 lakh in Q2 FY26.
  • Consolidated Revenue From Operations for Q2 FY27 decreased to Rs. 7,202.01 lakh, compared to Rs. 7,372.06 lakh in Q2 FY26.
📅 Company Track Record
Astec Lifesciences reported a consolidated loss after tax of Rs. 1,870.73 lakh for Q1 FY27 (quarter ended June 30, 2026). The current Q2 FY27 results show a further consolidated loss of Rs. 3,739.71 lakh, contributing to an accumulated half-year loss. The company was incorporated in 1994.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Astec Lifesciences' consolidated loss after tax for Q2 FY27?
Astec Lifesciences' consolidated Loss for the Period after tax was Rs. 3,739.71 lakh for the quarter ended September 30, 2026.
What was Astec Lifesciences' consolidated revenue from operations in Q2 FY27?
The consolidated Revenue From Operations for Astec Lifesciences was Rs. 7,202.01 lakh for the quarter ended September 30, 2026.
What is Astec Lifesciences' consolidated Basic EPS for Q2 FY27?
Astec Lifesciences reported a consolidated Basic Earnings per equity share (non-annualized) of Rs. (16.79) for the quarter ended September 30, 2026.
What was Astec Lifesciences' consolidated total assets as of September 30, 2026?
As of September 30, 2026, Astec Lifesciences' consolidated Total Assets stood at Rs. 79,441.82 lakh.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.